Related Experiment Videos
PET versus SPECT for determining myocardial tissue viability using fluorine-18-fluorodeoxyglucose
F V Schraml1, D R Driver, T Randolph
1National Naval Medical Center, Nuclear Medicine Division, Bethesda, MD 20889-5600, USA.
Journal of Nuclear Medicine Technology
|January 24, 1998
Summary
Fluorine-18 fluorodeoxyglucose (18F-FDG) myocardial imaging can assess heart muscle viability. A modified gamma camera offers an effective alternative to positron emission tomography (PET) scanners for this purpose.
Area of Science:
- Nuclear medicine
- Radiopharmaceutical imaging
- Cardiology
Background:
- The U.S. Food and Drug Administration regulates 18F-FDG.
- Institutional Review Board approval is necessary for its use in myocardial imaging.
- Assessing myocardial viability is crucial for patient management.
Purpose of the Study:
- To scientifically validate the use of 18F-FDG for assessing myocardial viability.
- To compare PET scanner methodology with modified gamma camera methodology for 18F-FDG imaging.
- To provide guidance for nuclear medicine professionals facing regulatory and acquisition challenges with 18F-FDG.
Main Methods:
- Literature review on the efficacy of 18F-FDG in myocardial viability assessment.
- Comparative analysis of PET scanner and modified gamma camera techniques for 18F-FDG imaging.
- Focus on 511-keV collimator-equipped gamma cameras.
Main Results:
- 18F-FDG is effective in assessing myocardial viability.
- Modified gamma camera imaging of 18F-FDG is a viable alternative to PET scanning.
- Both methods aid in distinguishing viable from scarred myocardium.
Conclusions:
- Modified gamma camera imaging of 18F-FDG is an effective alternative for myocardial viability assessment.
- This approach can be valuable for institutions navigating the acquisition and use of 18F-FDG.
- The findings support broader accessibility to myocardial viability imaging.